Literatur
-
1
Camm A J.
Atrial fibrillation: is there a role for
low-molecular-weight heparin?.
Clin Cardiol.
2001;
24
115-119
-
2
Cohen M, Demers C, Gurfinkel E P, Turpie A G, Fromell G J, Goodman S, Langer A, Califf R M, Fox K A, Premmereur J, Bigonzi F.
A comparison of low-molecular-weight heparin
with unfractionated heparin for unstable coronary artery disease.
Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary
Events Study Group.
N Engl J Med.
1997;
337
447-452
-
3
Koopman M M, Prandoni P, Piovella F, Ockelford P A, Brandjes D P, van der Meer J, Gallus A S, Simonneau G, Chesterman C H, Prins M H. The Tasman Study Group .
Treatment
of venous thrombosis with intravenous unfractionated heparin administered
in the hospital as compared with subcutaneous low-molecular-weight
heparin administered at home.
N Engl J Med.
1996;
334
682-687
-
4
Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie A G, Demers C, Kovacs M.
A comparison of low-molecular-weight heparin
administered primarily at home with unfractionated heparin administered
in the hospital for proximal deep-vein thrombosis.
N Engl
J Med.
1996;
334
677-681
-
5
Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J P, Azarian R, Laurent M, Hirsch J L, Ferrari E, Bosson J L, Mottier D, Beau B. The THESEE Study Group .
A
comparison of low-molecular-weight heparin with unfractionated heparin
for acute pulmonary embolism. Tinzaparine ou Heparine Standard: Evaluations
dans l’Embolie Pulmonaire.
N Engl J Med.
1997;
337
663-669
-
6
Tinmouth A H, Morrow B H, Cruickshank M K, Moore P M, Kovacs M J.
Dalteparin
as periprocedure anticoagulation for patients on warfarin and at
high risk of thrombosis.
Ann Pharmacother.
2001;
35
669-674
Autor
Priv.-Doz. Dr. Uta C. Hoppe
Klinik III für Innere Medizin, Universität
zu Köln
Joseph-Stelzmann-Straße 9
50937 Köln
